The Ripple Effects of Expanding Drug Negotiations Beyond Medicare | Opinion

In last year’s scramble to include government price controls on prescription drugs in President Biden’s Inflation Reduction Act, Democrats were willing to say almost anything. They reassured us that their scheme applied only to Medicare and would phase in slowly, with ample opportunity for stock-taking.

That was so 2022. This year, Democrats are letting the cat out of the bag. They want big government to set the prices for most new medicines, including those covered by private insurance plans. And they want it starting now.

Saul Anuzis is the president of the 60 Plus Association. He wrote this for